DexCom designs, develops, and commercializes continuous glucose monitoring systems for people with diabetes and healthcare providers. Products include G6 and G7 CGM systems, Share remote monitoring, Real-Time API, and ONE device replacing finger stick testing. The company also submitted FDA review for Stelo for type 2 diabetes patients.
| Indicator | Value |
|---|---|
| PER | 54.8 |
| EV/EBITDA | 35.5 |
| Price/Free Cash Flow' | 50.1 |
| ROIC | 21.1% |
| Net Debt/EBITDA | 2.1 |